Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.

Clin Cancer Res · 2023 · PMC9811162 · PMID 36165912

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

a nonsignificant trendP = 0.065so close (0.05 < p ≤ 0.1)

A nonsignificant trend towards better clinical benefit was observed with higher palbociclib doses ( P = 0.065; Supplementary Table S8).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.